INDICATIONS AND USAGE Afatinib is a kinase inhibitor indicated for: • First-line treatment of patients with…
INDICATIONS AND USAGE Erlotinib is a kinase inhibitor indicated for: · The treatment of patients with metastatic…
INDICATIONS AND USAGE Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with…
TYVYT® (sintilimab injection) is a fully human IgG4 monoclonal antibody, which specifically binds to PD-1 expressed on…
About Savolitinib Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical…
About Furmonertinib Furmonertinib Mesilate acts as an anti-cancer agent. It is formulated as tablets for oral…
About Tepotinib Tepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping…
About Adagrasib Adagrasib is a prescription medicine used in adults: alone to treat non-small cell lung…
About Cejemly® (Sugemalimab) The anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat® transgenic animal…
About Pralsetinib Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth. Pralsetinib is a medication approved for RET mutation-positive medullary…
ABout Crizotinib Crizotinib is a prescription medicine used to treat people with non-small cell lung cancer…
About Repotrectinib Repotrectinib is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is…
About Encorafenib Encorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets…
Melanoma Indicated in combination with encorafenib for patients with unresectable or metastatic melanoma with a BRAF…
Larotrectinib Larotrectinib is a medication for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. …
Larotrectinib Larotrectinib is a medication for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. …
Copyright © 2021-2022 LienTeh.net All rights reserved.
